Thus, toll-like receptor 9 (TLR9) elicits an innate-immune response and clearance of Aβ through activation by unmethylated cytosine-guanosine (CpG) reducing AD pathology in mice (Scholtzova et al., 2014). This evidence concerns the gene TLR9 and Alzheimer disease.